AZTA Stock Overview
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Azenta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.09 |
| 52 Week High | US$69.16 |
| 52 Week Low | US$36.01 |
| Beta | 1.49 |
| 1 Month Change | -9.91% |
| 3 Month Change | -20.30% |
| 1 Year Change | 27.83% |
| 3 Year Change | -51.53% |
| 5 Year Change | 36.93% |
| Change since IPO | 420.90% |
Recent News & Updates
Recent updates
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
Apr 05
Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price
Dec 28Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?
Nov 07At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?
Sep 13Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Aug 09Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?
Jun 01Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)
May 11Is Azenta, Inc. (NASDAQ:AZTA) Worth US$42.5 Based On Its Intrinsic Value?
Mar 30Azenta: Putting Its Cash Hoard To Use
Oct 02Azenta to acquire vaccine cold chain firm B Medical Systems for €410M
Aug 08Brasada Capital - Azenta Life Sciences: No Ordinary Company
Jul 26Azenta stock falls postmarket as prelim Q3 revenue misses Street estimates
Jul 13Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
May 05Should You Think About Buying Azenta, Inc. (NASDAQ:AZTA) Now?
Apr 14Azenta (NASDAQ:AZTA) Has A Pretty Healthy Balance Sheet
Feb 03Shareholder Returns
| AZTA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.8% | 4.1% | 1.2% |
| 1Y | 27.8% | 4.7% | 24.9% |
Return vs Industry: AZTA exceeded the US Life Sciences industry which returned 5.2% over the past year.
Return vs Market: AZTA exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| AZTA volatility | |
|---|---|
| AZTA Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AZTA's share price has been volatile over the past 3 months.
Volatility Over Time: AZTA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 3,500 | Steve Schwartz | www.azenta.com |
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions.
Azenta, Inc. Fundamentals Summary
| AZTA fundamental statistics | |
|---|---|
| Market cap | US$2.93b |
| Earnings (TTM) | -US$17.37m |
| Revenue (TTM) | US$641.02m |
4.5x
P/S Ratio-167.2x
P/E RatioIs AZTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZTA income statement (TTM) | |
|---|---|
| Revenue | US$641.02m |
| Cost of Revenue | US$380.57m |
| Gross Profit | US$260.45m |
| Other Expenses | US$277.82m |
| Earnings | -US$17.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 40.63% |
| Net Profit Margin | -2.71% |
| Debt/Equity Ratio | 0% |
How did AZTA perform over the long term?
See historical performance and comparison